My Companies
Notification
Account
Log Out
Login
Suven completed global Phase 3 enrollment for Masupirdine in Alzheimer’s agitation, randomizing 424 patients versus 375 planned. LPLV is expected by December 2026, database lock by March 2027 and topline results by May 2027. Context: enrollment completed ahead of the previously stated end-September target.
Suven Life Sciences To Invest USD 100 Million In Singapore Subsidiary
Suven Life Sciences Reports Positive Phase 2b Depression Trial Results